Krabbe disease is a rare inherited leukodystrophy caused by deficient activity of the enzyme galactocerebrosidase, usually because of disease-causing variants in both copies of the GALC gene. It affects myelin, the insulating material surrounding many nerve fibers, in both the central nervous system and the peripheral nervous system. The most familiar form begins in infancy and progresses rapidly, but onset can occur in childhood, adolescence, or adulthood. Clinical severity and progression vary substantially, particularly in later-onset disease.
Biological basis
Krabbe disease belongs to the lysosomal storage diseases, a group of disorders involving impaired processing of substances within lysosomes, the cell compartments responsible for breaking down and recycling many molecules.
Galactocerebrosidase, also called galactosylceramidase, is a lysosomal enzyme that breaks down certain galactose-containing lipids. Its substrates include galactosylceramide, an important component of myelin, and psychosine, also known as galactosylsphingosine.
In Krabbe disease, psychosine accumulates and is toxic to myelin-producing cells: oligodendrocytes in the central nervous system and Schwann cells in peripheral nerves. Their injury contributes to demyelination, impaired nerve signaling, and subsequent damage to nerve fibers. Inflammatory responses also contribute to the disease process.
The alternative name globoid cell leukodystrophy refers to characteristic enlarged, often multinucleated cells derived from macrophages that appear in affected nervous tissue. These cells accompany myelin breakdown and abnormalities of the brain’s white matter. Their presence is a pathological hallmark, but examination of nervous-system tissue is not generally required for diagnosis.
Genetics and inheritance
Krabbe disease usually follows autosomal recessive inheritance. An affected person has disease-causing variants in both copies of GALC, which is located on chromosome 14. Parents who each carry one disease-causing variant are usually unaffected.
When both parents are carriers, each pregnancy has:
- A 25% probability of a child inheriting both disease-causing variants and being affected.
- A 50% probability of a child being an unaffected carrier.
- A 25% probability of a child inheriting neither familial variant.
These probabilities apply independently to each pregnancy.
Many different GALC variants have been identified. Some are strongly associated with severe early disease, but genotype does not always predict age at onset or subsequent progression. Very low enzyme activity can also result from combinations of variants that do not cause clinical disease, complicating interpretation of screening results.
Genetic counseling addresses inheritance, carrier testing, and reproductive testing. When the familial variants are known, prenatal diagnosis and preimplantation genetic testing may be possible.
Clinical forms and manifestations
Krabbe disease forms a clinical continuum rather than a set of completely separate subtypes. Published classifications use somewhat different age boundaries, so age at symptom onset is more informative than a subtype label alone.
Infantile disease
The classic infantile presentation begins during the first months of life, often after an apparently normal early period. Early manifestations may include:
- Marked irritability and unusually strong responses to touch or sound.
- Feeding difficulties and poor weight gain.
- Increasing stiffness or abnormal muscle tone.
- Delayed development or loss of acquired skills.
Progression can produce severe spasticity, impaired swallowing, visual loss, seizures, and profound motor disability. Peripheral nerve involvement may cause reduced reflexes or slowed nerve conduction, even when central nervous system injury produces stiffness elsewhere. Advanced disease can impair breathing and the ability to manage secretions.
Untreated classic early-infantile disease is often fatal within the first two years of life, although survival varies.
Later-onset disease
Disease beginning later in infancy, childhood, adolescence, or adulthood is more variable. Manifestations can include progressive walking difficulty, leg stiffness and weakness, impaired coordination, visual disturbance, or peripheral neuropathy. Some patients initially have predominantly motor or visual symptoms.
Progression may occur over months or over many years. Cognitive function can be relatively preserved in some later-onset cases, but this is not universal. Age at onset alone does not reliably determine an individual’s course.
Diagnosis
Diagnosis combines clinical assessment with biochemical and molecular testing. No single finding is sufficient in every setting.
Enzyme and genetic testing
Galactocerebrosidase activity can be measured in white blood cells or cultured skin fibroblasts. Markedly reduced activity supports the diagnosis, while molecular testing seeks disease-causing variants in both copies of GALC.
An important limitation is pseudodeficiency: certain variants reduce activity measured by a laboratory assay without causing Krabbe disease. Consequently, low enzyme activity alone does not establish the diagnosis or reliably predict disease severity.
Blood psychosine measurement provides additional information. Markedly elevated psychosine is strongly associated with severe infantile disease and is particularly valuable when interpreting abnormal newborn screening results. Lower or normal concentrations do not exclude every later-onset presentation.
Neurological investigations
Magnetic resonance imaging can reveal abnormalities of cerebral and cerebellar white matter and other myelinated pathways. Imaging patterns vary with age and disease stage; early imaging may not yet show extensive abnormalities.
Nerve conduction studies can demonstrate peripheral demyelination. Protein concentration in the cerebrospinal fluid is often elevated, but this finding is nonspecific. Vision and hearing pathway tests may help characterize neurological involvement.
The differential diagnosis includes other leukodystrophies, inherited neuropathies, and metabolic or neurodegenerative disorders that cause developmental regression or progressive spasticity.
Newborn screening
Some newborn screening programs test galactocerebrosidase activity in dried blood spots. Programs may use psychosine measurement and genetic testing as additional steps to distinguish infants at high risk of early disease from carriers, individuals with pseudodeficiency, and those with uncertain later-onset risk.
Screening is important because the opportunity for effective disease-modifying treatment in infantile Krabbe disease can precede recognizable symptoms. However, screening also creates substantial interpretive challenges:
- An abnormal enzyme result is not itself a diagnosis.
- Some findings do not reliably establish whether symptoms will develop or when.
- Confirmatory testing and specialist assessment are time-sensitive for infants with biochemical evidence of severe disease.
These uncertainties distinguish screening for Krabbe disease from conditions in which a positive result predicts a more uniform clinical course.
Treatment and supportive care
Hematopoietic stem cell transplantation
Hematopoietic stem cell transplantation is the established disease-modifying treatment for selected patients. Donor-derived cells can supply functional enzyme and may slow neurological deterioration.
In severe infantile disease, the greatest benefit has been observed when transplantation occurs before symptoms, typically very early in life. Transplantation after substantial neurological injury generally has much less effect because existing damage cannot reliably be reversed. Some selected patients with later-onset disease may also benefit.
Transplantation is not a cure. Even after presymptomatic treatment, patients can develop significant motor impairment and peripheral nerve disease. The procedure carries serious risks, including infection, conditioning-related toxicity, graft-versus-host disease, and transplant-related death.
Supportive management
Supportive care addresses feeding and swallowing difficulties, respiratory complications, seizures, abnormal muscle tone, discomfort, and communication needs. Physical therapy, occupational therapy, positioning, and assistive equipment may help preserve function and manage secondary complications.
Palliative care can be provided alongside disease-directed treatment, focusing on symptom control, family support, and quality of life.
Epidemiology and history
Krabbe disease is rare. Estimates have often placed its occurrence at approximately one in 100,000 live births, but reported rates vary by population and method of ascertainment. Higher frequencies occur in some populations because of founder variants. Later-onset disease can be underrecognized, making its frequency less certain.
The disorder is named after the Danish neurologist Knud Krabbe, who described its characteristic infantile clinical and pathological features in 1916.
Research
Research includes gene therapy, approaches to reducing psychosine accumulation, and strategies to improve delivery of functional enzyme to nervous tissue. Combination treatments are also under investigation because central and peripheral nervous system disease may respond differently.
Major challenges include treating patients before irreversible injury, reaching affected cells throughout the nervous system, and identifying measures that reliably predict long-term function. Changes in enzyme activity or psychosine concentration can demonstrate biological effects, but do not by themselves establish durable neurological benefit.